Anti-rabies monoclonal antibody(Changchun Bcht Biotechnology)

全人源抗狂犬病毒单克隆抗体（长春百克生物）

Report date: 2024/07/29 20:00:43

Base Information

Drug NameAnti-rabies monoclonal antibody(Changchun Bcht Biotechnology)
Drug Alias NameNatural full human monoclonal antibody CBB 1(Changchun Bcht Biotechnology)Rabies mAb CBB 1(Changchun Bcht Biotechnology)Rabies Monomab CBB 1(Changchun Bcht Biotechnology)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionRabies virus neutralization
TargetsRabies virus
Therapy Area/IndicationsRabies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhuhai Trinomab Pharmaceutical Co LtdChangchun Bcht Biotechnology Co
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChangchun Bcht Biotechnology Co
Inactive CompaniesZhuhai Trinomab Pharmaceutical Co Ltd
Active IndicationsRabies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A